Clovis Oncology, Inc. , announced that non-clinical data from studies evaluating FAP-2286 (targeting Fibroblast Activation Protein in tumors) and Rubraca(a small molecule targeting multiple tumours including ovarian metastatic castration-resistant prostate cancers), two new molecules being investigated for targeting cancerswill be presented at the merican Association for Cancer Research (AACR) Annual Meeting 2022, held April 8-13, 2022, in New Orleans.
The
company announced that in LuMIERE study,
lutetium-177 (177Lu)-FAP-2286
showed longer tumor retention and greater tumor inhibition as compared
to lutetium-177 (177Lu)-FAPI-46, a FAP-targeted radiotracer developed for
therapeutic applications at the University of Heidelberg, Germany.
To
read more please visit:
Source: CLOVIS ONCOLOGY